Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About MCN
  • Careers
  • MCNTalk
  • Contact Us

MCN | Medical Consultants Network

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / The New Law Giving Power to Drug Companies

October 17, 2017

The New Law Giving Power to Drug Companies

In recent years the DEA has been dealing with a vicious cycle that has led to the opioid epidemic we are in the midst of now: Some drug companies do not report suspicious orders of narcotics, some doctors write fraudulent prescriptions, some pharmacists look the other way when filling them, and all of this can culminate with a person having an opioid prescription without ever having seen a doctor.

The DEA once had the power to stop suspicious pharmaceutical sales in order to keep dangerous narcotics off the street, but a new law that passed in 2016 makes it nearly impossible for the DEA to stop a pharmaceutical company’s distribution of products when the company fails to observe federal law.

This investigative piece by The Washington Post delves into how and why this law was able to pass through Congress and asks those who are working against the law to stop the resulting flow of opioids into our streets. The article examines an unfortunate trend of former DEA officials changing careers to work for the pharmaceutical industry — a move that allows them to bring with them extensive knowledge about how to craft legislation that can protect drug companies against the power of the DEA. Those working in the  industry defend the new law, stating that it prevents any delays or disruptions for patients in need of medication. But as deaths rise and suspension orders against doctors fall it is clear that the impact of this law is much more complicated than that.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • The Quality Divide: What Makes a Quality IME Physician?
  • The Quality Divide: Is Your Vendor Driving IME Excellence?
  • The Quality Divide: When and How to Request an IME?
  • April Clinic Calendars Are Available
  • MCN’s Client Portal Login Page is Changing

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About MCN
  • Careers

Division Headquarters

MCN
1200 5th Ave., Ste. 650
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2023 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap